22 May 2013
Keywords: six, month, pfs, ph, melanoma, study, roche
Article | 01 June 2009
Swiss drug major Roche and US partner Plexxikon reported strong interim results from a Phase I study of PLX4032 (R7204) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 June 2009
21 May 2013
© 2013 thepharmaletter.com